Evotec (NASDAQ:EVO) Shares Gap Down Following Weak Earnings

Key Points

• Evotec shares fell sharply, opening at $2.02 after closing at $2.19, following quarterly earnings that missed expectations. The company reported a loss of $0.14 per share versus the expected $0.05 loss, while revenue of $161.2 million trailed estimates of $173.87 million.
• Analyst sentiment has weakened, with several firms downgrading the stock or cutting price targets. Evotec now has a consensus “Hold” rating and an average price target of $3.00.
• The company remains unprofitable, reporting a negative net margin of 26.20% and negative return on equity of 24.93%; institutional investors and hedge funds own 5.81% of its shares.

Shares of Evotec AG (NASDAQ:EVO - Get Free Report) gapped down prior to trading on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $2.19, but opened at $2.02. Evotec shares last traded at $1.9950, with a volume of 4,992 shares trading hands.

The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). The company had revenue of $161.20 million during the quarter, compared to analyst estimates of $173.87 million. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. HC Wainwright reduced their price target on Evotec from $7.00 to $4.00 and set a "buy" rating for the company in a report on Wednesday, July 15th. Berenberg Bank downgraded Evotec from a "buy" rating to a "hold" rating in a report on Thursday, July 16th. TD Cowen lowered shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 price objective on the stock. in a research report on Wednesday, July 15th. Wall Street Zen cut shares of Evotec from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Evotec in a research report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Evotec presently has a consensus rating of "Hold" and a consensus price target of $3.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Apollon Wealth Management LLC bought a new position in shares of Evotec in the 1st quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its position in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock worth $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE grew its holdings in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Marshall Wace LLP acquired a new position in Evotec during the fourth quarter valued at approximately $40,000. Finally, XTX Topco Ltd bought a new position in shares of Evotec in the second quarter valued at approximately $66,000. Institutional investors and hedge funds own 5.81% of the company's stock.

Evotec Stock Performance

The stock's 50-day moving average price is $2.41 and its 200 day moving average price is $2.82. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source